I have been buying today.
This is an amazing coup to land this world leader in heart matters and it brings the muscle that htw needs to make it big in the US. This man would not leave Boston Scientific unless he had total faith in this product. Toss in the genius of Dr Bud Frasier and this company is set to storm the Nasdaq down the track.
HeartWare has appointed Mr Doug Godshall as the Company’s new Chief Executive Officer:
- Doug takes over from Stuart McConchie who has resigned from the position
- Doug is a 15 year veteran of Boston Scientific, one of the world’s largest medical device companies. Most recently, until accepting the HeartWare position, he was President of the Vascular Surgery division, with responsibility for a business employing 600 staff and generating revenues of US$100 million. He previously spent 5 years as VP Business Development, during which time he negotiated over 70 transactions and represented Boston Scientific on the Boards of 11 companies.
- As at today’s date, HeartWare’s first two patients have been supported for a cumulative period of 297 days. The pumps have performed flawlessly and the patients have recovered well. Subject to patient availability, a third implant is imminent and further implants are expected over ensuing weeks.
About HeartWare
HeartWare is developing a family of proprietary circulatory assist devices to treat patients with heart failure. HeartWare’s lead device, the HVADTM, commenced human clinical trials in March 2006. First sales are anticipated in late 2007. With a volume of 45cc, the HVAD is the smallest “3rd generation” pump and the only full output device implantable within the pericardial space.
In parallel with the HVAD clinical development, HeartWare is pursuing its MVAD program, aimed at developing a family of miniaturized cardiac assist devices, implantable by minimally invasive surgical techniques. The current MVADTM prototype, approximately one tenth the volume of the HVAD, commenced animal studies in August 2005.
HTW
heartware limited
